Abstract. Achilles tendons have a very poor capacity for intrinsic regeneration. The cell-based treatment strategy for Achilles tendinitis includes the application of mesenchymal stem cells (MSCs), which have high proliferative and multipotent differentiation ability, and is a promising approach. The aim of the present study was to explore the tenogenic potential of human menstrual blood stromal stem cells (MenSCs) in a co-culture system and to compare the tenogenic capability under normoxic and hypoxic conditions. MenSCs were co-cultured indirectly with Achilles tendon cells in a Transwell co-culture system for 1, 2, or 3 weeks in two different concentrations of oxygen (20 and 2% O₂), whereas the control contained only MenSCs. The extracellular matrix of MenSCs in each system was evaluated by Alcian blue staining assay, histological staining, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and western blot analysis. Alcian blue staining assay revealed a significant increase (P<0.05) in proteoglycan secretion by the differentiated MenSCs. Identical results were obtained by RT-qPCR for collagen I, which was validated by western blot analysis. Considerably increased collagen I and collagen III gene expression levels were exhibited by cells in the co-culture treatment group when compared with the control (P<0.05); however, no significant difference was detected between the normoxic (20% O₂) and hypoxic treatment (2% O₂) groups.

RT-qPCR was utilized to determine the expression levels of thrombospondin 4, scleraxis and tenascin C in the differentiated MenSCs; a significant increase in the expression of these specific genes was indicated in the co-culture treatment group compared with the control (P<0.05). Although the expression levels were markedly higher in hypoxia than in normoxia conditions, this difference was not significant. To conclude, the present study indicated that MenSCs manifested a strong proliferative and multipotent capacity for differentiation and differentiated into Achilles tenogenic cells. Therefore, the use of MenSCs may be considered in Achilles tendinitis therapy.

Introduction

A number of people, particularly those who have engaged in sports activities, often experience heel pain. Achilles tendinitis is generally recognized to be the predominant cause of heel pain (1). Typically, the treatment methods applied at present, such as surgical or non-operative therapy, exert limited effects in treating the symptoms, rather than targeting the root cause of Achilles tendinitis.

Achilles tendinitis is considered a non-inflammatory condition and has been characterized as either lipid or mucoid degeneration (2). During this process, the normal white, glistening appearance of the tendon is lost, and it becomes grayish or brown and is mechanically softer (2). In addition to its color and substance changes, the damaged Achilles tendon is characterized by increased vascularization or neovascularization (3). These alterations lead to an abrupt reduction in the formation of matrix components, such as collagen type I (Col I), collagen type III (Col III), subsequently, substantial impairment is inflicted on the tendon, and eventually Achilles tendinitis occurs (4).

Previous reports have suggested that the application of stem cells can accelerate the healing of the Achilles tendon in animal models (5,6). Due to the proliferation capacity and pluripotentiality of MSCs, the effects of the transplantation of stem cells may be exerted not only through direct differentiation of the mesenchymal stem cells, but also via the release of paracrine factors, such as growth factors and cytokines, secreted by the cells (7). In previous analysis, the most common types of
MSCs utilized in experiments are bone marrow mesenchymal stem cells (BMSCs) (8) and adipose-deprived mesenchymal stem cells (9). However, certain disadvantages in the application of these adult stem cells have been identified, including the invasiveness of the procedures for the collection of MSCs and the poor potential for proliferation, which is lower than that of embryonic stem cells (10).

Stromal stem cells obtained from menstrual blood (MenSCs) have been utilized as a novel source in previous studies (11,12), demonstrating important advantages, such as a decreased hazard of anomalies in the karyotype and a minimized possibility for tumor formation and acceleration in animal models (13). MenSCs are derived by non-invasive methods, thus this cell type is ethically suitable and autologous. Therefore, MenSCs can be considered the perfect stem cell type for the treatment of Achilles tendinitis.

In previous research, tendon genes, such as Col I and Col III, were typically used to assess the tenogenic differentiation of MSC. Specific human tendon genes, including thrombospondin 4 (THBS4), scleraxis (Scx), and tenasin C (TENC), were identified through a comparison between the gene expression rates of tenogenic cells and Achilles tendon cells (14). However, little is known on the exact MSC commitment process and the mechanism of differentiation. The present study aimed to establish a co-culture system of MenSCs and Achilles tendon cells in normoxia (20% O₂) and hypoxia (2% O₂) conditions, respectively. The extracellular matrix (ECM) and the distinctive human tendon genes were utilized to assess the tenogenic differentiation of MenSCs.

Materials and methods

Ethics statement. The present study was conducted according to the tenets of the Declaration of Helsinki. All patients were candidates for Achilles tendon surgical repair and gave their written informed consent and approved the use of the resected Achilles tendon from both broken ends for further basic research. The study design and the protocol had been granted a written agreement by the Second Affiliated Hospital of Wenzhou Medical University Research Ethics Committee. In the experiments the part of the Achilles tendon that required removal before suture was used, which prevented any secondary damage to the tissue.

Culture of Achilles tendon cells (ATCs). Between January and June 2012, tissue samples from the Achilles tendons were collected from 3 patients (2 male, 1 female; age, 23-45 years), and June 2012, tissue samples from the Achilles tendons were collected from 3 patients (2 male, 1 female; age, 23-45 years), suffering from closed Achilles tendon rupture, during surgery. Patients exhibited no underlying health problems or serious medical conditions. Tissues were washed with phosphate-buffered saline (PBS) and digested enzymatically with 0.2% collagenase type II (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) at 37°C for 6 h. Subsequently, the tissue debris was removed by passage through a 200-μm filter and the obtained ATCs were centrifuged at 250 x g for 10 min at 4°C and resuspended in Dulbecco’s modified Eagle’s medium (DMEM) and Ham’s F-12 Nutrient Mixture, supplemented with 10% fetal bovine serum (FBS) (all Gibco; Thermo Fisher Scientific Inc., Waltham, MA, USA) and 1% penicillin/streptomycin (Beijing Solarbio Science & Technology, Beijing, China). The suspension was incubated at 37°C in a humidified atmosphere containing 5% CO₂. The medium was changed 2-3 times a week. Cells were observed under a light microscope (magnification, x100).

Culture of human MenSCs. Human MenSCs were purchased from S-Evans Biosciences (Hangzhou, China). Identification of cell surface markers, such as cell differentiation (CD)-73, CD-90, CD-105, CD-14, CD-19, CD-34, CD-35, and human leucocyte antigen antigen D-related (HLA-DR) were examined by S-Evans Biosciences with flow cytometry. The cells were cultured in DMEM/F-12 media and 10% FBS (both Gibco; Thermo Fisher Scientific, Inc.); then, they were incubated at a 37°C, in a 5% CO₂ environment.

Co-culture of MenSCs and ATCs. A co-culture system was constructed with a Transwell chamber (Corning Inc., Corning, NY, USA), which could be inserted into the wells of 6-well plates. MenSCs were seeded on 6-well tissue culture polystyrene plates (Corning Inc.) at a density of 1x10⁴ cells/well, whereas ATCs were seeded at the ratio of 1:1 with MenSCs on the membrane (polyethylene terephthalate, pore size, 0.4 mm) of the Transwell chamber. ATCs and MenSCs were incubated for 1, 2, and 3 weeks at 37°C in a humidified atmosphere with either 95% air (21% O₂) plus 5% CO₂ (designated as normoxia) or with 2% O₂ plus 5% CO₂ and 93% N₂ (low O₂ tension) with a medium change every 2-3 days. MenSCs (1x10⁴) cultured in 6-well plates without ATCs were used as the control group. The culture medium was replaced every 3 days.

Alcian blue staining. Following co-culture for 2 weeks, MenSCs from each group were fixed in 4% paraformaldehyde (PFA), washed with PBS and stained with 0.5% Alcian blue (Sigma-Aldrich; Merck Millipore) in 3% acetic acid (pH 2.5) for 30 min. Cells were visualized and images were captured using light microscopy (magnification, x200; Leica DM 2500; Leica Microsystems GmbH, Wetzlar, Germany). Image-Pro Plus (IPP) software (version 6.0; Media Cybernetics, Inc., Rockville, MD, USA) was used to evaluate the mean stain density of each image.

Immunohistochemical staining. Glass coverslips (0.17 mm) with MenSCs following 1, 2, and 3 weeks of co-culture were fixed with 4% PFA in PBS at room temperature for 20 min and washed with PBS. Following permeation with Triton X-100 for 10 min and inhibition of endogenous peroxidase activity with 3% hydrogen peroxide for 15 min. MenSCs were blocked with 5% goat albumin in PBS for 30 min at 37°C. Subsequently, cells were incubated with an antibody against THBS4 (rabbit polyclonal; 1:800 dilution; sc-7657-R; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at 4°C overnight and washed with PBS 3 times, followed by incubation with a horseradish peroxidase-conjugated secondary antibody (1:200 dilution; PV-6001; ZSGB-BIO, Beijing, China) at 37°C for 30 min. A DAB detection kit (Dako North America, Inc., Carpenteria, CA, USA) was utilized until desired staining intensity developed, and the cells were counterstained with hematoxylin. Subsequently, the samples were observed under a light microscope at a magnification of x10 (Leica DM 2500). Quantitative analysis of staining was performed using IPP.
software (version 6.0; Media Cybernetics, Inc.) to evaluate the mean stain density of each image.

**Quantitative real-time polymerase chain reaction (RT-qPCR).** RT-qPCR was used to quantify the mRNA expression of Col I, Col III, THBS4, TENC, and Scx. RNA was isolated from each group by using TRIzol reagent (Invitrogen; Thermo Fisher Scientific Inc.) according to the manufacturer’s instructions and the concentration of total RNA was determined using a spectrophotometer (DU -500; Beckman Coulter, Inc., Fullerton, CA, USA) at 260 nm wavelength. First-strand cDNA was synthesized in a 20 µl reaction system containing: 11 µl DEPC ddH_2O with total RNA (2 µg), 1 µl Oligo (dT) 18 primer, 4 µl 5x Reaction buffer, 2 µl 10 mM dNTP mix, 1 µl Ribolock RNase inhibitor, and 1 µl RevertAid M-MULV reverse transcriptase (MBI Fermentas, Sankt Leon-Rot, Germany). qPCR was performed in triplicate using a CFX96 Real-Time PCR system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) under the following conditions: 10 min at 95˚C, followed by 40 cycles of 15 sec at 95˚C and 1 min at 60˚C for qPCR amplification. The reaction was performed in a total volume of 20 µl, containing 10 µl SYBR Green Master Mix (Bio-Rad Laboratories, Inc.), 2 µl cDNA, 1 µl each primer and 6 µl sterile distilled water. Target gene expression was calculated using the 2^ΔΔCq method (15) and normalized to 18S ribosomal RNA. The primers used are indicated in Table I.

**Western blot analysis.** Cells from different groups were harvested and lysed in a standard buffer (Beyotime Institute of Biotechnology, Haimen, China), and the total protein was extracted by using a Western and IP Cell Lysis kit (Beyotime Institute of Biotechnology). Cell lysates were separated and collected by centrifugation at 12,000 x g for 10 min at 4˚C. Protein concentrations were determined using an enhanced bicinchoninic acid assay kit (Beyotime Institute of Biotechnology). Equal quantities (30 µg) of protein from each sample were separated by 10% SDS PAGE and transferred onto nitrocellulose membranes. Following washing three times with TBS containing 0.1% Tween-20 for 5 min, non-fat milk was utilized to block non-specific blinding and the membranes were incubated overnight at 4˚C with a rabbit polyclonal antibody conjugated with THBS4 (rabbit polyclonal; 1:1,000 dilution; sc-7657-R; Santa Cruz Biotechnology, Inc.), COL I (goat polyclonal; 1:600 dilution; sc-8784; Santa Cruz Biotechnology, Inc.), and GAPDH (rabbit polyclonal; 1:1,000 dilution; BS60630; Bioworld Technology, Inc., St. Louis Park, MN, USA). Following washing three times with TBS containing 0.1% Tween-20 for 5 min and incubation for 2 h at room temperature with the following horseradish peroxidase-conjugated secondary antibodies: Rhodamine (TRITC), AffiniPure Rabbit Anti-Goat IgG (CW0168) and Goat anti Rabbit IgG (CW0111; all 1:3,000 dilution; Beijing ComWin Biotech Co., Ltd., Beijing, China); the membranes were treated with enhanced chemiluminescence (ECL) Plus reagent (Bio-Rad Laboratories, Inc., followed by detection using the ChemiDoc XRS+ system with Quantity ONE software (1,708,265; Bio-Rad Laboratories, Inc.) software.

**Statistical analysis.** Data are expressed as the mean ± standard deviation. Statistical evaluation of the differences between and within the groups was performed using one-way analysis of variance followed by post-hoc Tukey’s test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Cell surface markers.** As shown in Fig. 1, the following multipotent surface markers are present on mesenchymal stem cells: CD73, CD90, and CD105; whereas CD14, CD19, CD34, CD35, and HLA-DR were absent on these cells, which were also absent in the cells identified by Cui et al (16). Furthermore the MenSCs appear to have similar characteristics as the human endometrial stem cells identified by Cho et al (17). The expression of multipotent markers is indicative of cells that have the capacity to differentiate into cell types derived from multiple germ layers.

**Alcian blue staining.** Following 2 weeks of co-culture, Alcian blue staining was applied to stain the proteoglycan secreted by MenSCs. MenSCs from the control treatment were stained negatively (Fig. 2A and B). Conversely, staining of MenSCs
was substantially promoted, and Alcian blue metachromasia was evident in MenSCs under hypoxic (Fig. 2C) and normoxic (Fig. 2D) conditions. According to Fig. 2E, higher proteoglycan secretion was exhibited in the hypoxic cell group than in the normoxic group; however, no significant difference was established between these groups (P>0.05).

**Immunohistochemical staining.** THBS4 immunohistochemical staining was implemented to identify the level of THBS4 secretion by MenSCs. Following co-culture with ATCs, MenSCs from the control group were stained negatively, whereas MenSCs in the hypoxic treatment group were stained more intensely than those in the normoxic group (Fig. 3A-H). The results were more obvious in Fig. 3I, which was processed by IPP 6.0.

**RT-qPCR.** Following co-culture, RT-qPCR was performed to analyze the expression of ECM genes (collagen I, collagen III, THBS4, scleraxis, and tenascin C). By the end of the 3-week co-culture, gene expression levels of Col I, Col III, THBS4, TENC, and Scx in the normoxic and hypoxic groups were significantly higher than those in the control group (P<0.05; Fig. 4A-E, respectively). Moreover, the expression of ECM genes within the normoxic and hypoxic treatments were significantly upregulated (P<0.05; Fig. 4). Nevertheless, the expression of Col I, Col III, THBS4, TENC, and Scx in the
Figure 2. Alcian blue staining of MenSCs. MenSCs were co-cultured indirectly with Achilles tendon cells in a Transwell co-culture system in two different concentrations of oxygen (20% O₂, normoxic conditions and 2% O₂, hypoxic conditions), whereas the control contained only MenSCs. Control MenSCs under (A) hypoxic and (B) normoxic conditions. MenSCs under (C) hypoxic and (D) normoxic conditions. The co-culture group exhibited a higher intensity metachromatic effect when compared with the control group. (E) Alcian staining density of each group. Data are presented as the mean + standard deviation. *P<0.05 vs. control. Scale bar, 100 µm (magnification, x10). MenSCs, menstrual blood stromal stem cells.

Figure 3. Immunohistochemical staining of MenSCs. Immunohistochemical staining revealed the secretion of THBS4 by MenSCs. MenSCs were co-cultured indirectly with Achilles tendon cells in a transwell co-culture system, for 1, 2, or 3 weeks in two different concentrations of oxygen (20% O₂ and 2% O₂), whereas the control contained only MenSCs. (A) Normoxic control. (B) Normoxic MenSCs co-cultured for 1 week. (C) Normoxic MenSCs co-cultured for 2 weeks. (D) Normoxic MenSCs co-cultured for 3 weeks. (E) Hypoxic control. (F) Hypoxic MenSCs co-cultured for 1 week. (G) Hypoxic MenSCs co-cultured for 2 weeks. (H) Hypoxic MenSCs co-cultured for 3 weeks. (Scale bar 100 µm). (I) THBS4 staining density of each group, quantified by Image Pro Plus 6.0 software. THBS4 immunohistochemical staining was positive, showing a strong color in normoxic and hypoxic groups (B, C, D, F, G, and H: color intensity D>C>B; H>G>F; F>B; G>C; H>D), whereas it was not obvious in the control group (A and E). Data are presented as the mean + standard deviation. MenSCs, menstrual blood stromal stem cells; THBS4, thrombospondin 4.
normoxic cell group did not differ significantly when compared with the hypoxic group (P>0.05; Fig. 4A-E, respectively).

**Western blot analysis.** Western blotting was applied to detect Col I and THBS4 protein and quantify their content. Following 3 weeks of co-culture, Col I and THBS4 proteins were present in all groups. Quantities of these proteins in the hypoxic and normoxic groups were higher when compared with the control group. However, there was no marked difference between the quantities of the proteins mentioned in the cells under hypoxia and those under normoxia. GAPDH was used as a control. MenSCs, menstrual blood stromal stem cells; Col I, collagen type I; THBS4, thrombospondin 4; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

**Discussion**

Owing to the extremely poor self-healing capacity of the human tendon, Achilles tendinitis has long been a clinical challenge (18,19). Transplantation of MSCs provides an excellent solution for the treatment of Achilles tendinitis. Through
the implementation of this method, tenogenic differentiation is achieved and supplementation of the ECM is promoted, which stimulates the recovery of the degenerated tendon and leads to its healing.

Previous findings indicate that MenSCs, a new source of MSCs, have been successfully differentiated into chondrogenic, adipogenic, osteogenic, (20), neurogenic, and cardiogenic cell lineages (12). The results of these studies demonstrate the plasticity of MenSCs for potential research in regenerative medicine. However, it is remains uncertain whether this cell type is able to differentiate into tenogenic cell lineages. The present study examined for the first time the in vitro capacity for tenogenic differentiation of MenSCs. ATCs are located in a comparatively avascular tissue area, and their development is hindered by the phenotype drift and loss of functions (21). An exceedingly low number of arterioles in proximity to the Achilles tendon have been established in an examination of the local blood supply, which indicated that the low oxygen environment is the natural medium of the Achilles tendon (22). We hypothesized that the level of oxygen exerted an effect on the differentiation of MenSCs into tenogenic cells as ATCs exist and operate under hypoxic conditions. There is evidence that oxygen tension of 2% enhanced the differentiation of human MSCs into cells similar to nucleus pulposus cells (23) and chondrocytes (24). Thus, low oxygen tension (2% O2) was utilized to determine whether hypoxia was able to stimulate the differentiation of MenSCs into tenogenic cells. In the present study, the results of Alcian blue Staining revealed that the secretion of proteoglycan increased significantly in the differentiated MenSCs obtained from both co-culture groups. RT-qPCR analysis indicated identical findings for Col I, which was also confirmed by western blotting. Gene expression of Col I and Col III in the co-culture group were significantly higher when compared with the control group, which is important for maintaining the function of the Achilles tendon. However, no significant difference was observed between the normoxic and hypoxic group, after 3 weeks' co-culture with ATCs, successful differentiation of MenSCs into tenogenic cells was achieved, which induced the production of the extracellular matrix that was similar to the original and led to the expression of the specific AT markers (THBS4, TENC and Scx). In future, MenSCs may be considered a potent novel source of MSCs that may contribute substantially towards the further development of therapies to treat Achilles tendinitis.

In conclusion, in spite of the absence of a significant difference between the normoxic and hypoxic group, after 3 weeks' co-culture with ATCs, successful differentiation of MenSCs into tenogenic cells was achieved, which induced the production of the extracellular matrix that was similar to the original and led to the expression of the specific AT markers (THBS4, TENC and Scx). In future, MenSCs may be considered a potent novel source of MSCs that may contribute substantially towards the further development of therapies to treat Achilles tendinitis.

Acknowledgements

Financial support for the present study was provided by The Foundation of ZheJiang Medicine and Health Subject (grant no. 201341061) and The WenZhou Technology Bureau (grant no. Y20100357).

References

1. Garcia CR, Martin RL, Houck J and Wukich DK; Orthopaedic Section of the American Physical Therapy Association: Achilles pain, stiffness, and muscle power deficits: Achilles tendinitis. J Orthop Sports Phys Ther 40: A1-A26, 2010.
2. Khan KM, Cook JL, Bonar F, Harcourt P and Astrom M: Histopathology of common tendinopathies. Update and implications for clinical management. Sports Med 27: 393-408, 1999.
3. Knobloch K, Kraemer R, Lichtenberg A, Jagodzinski M, Gossling T, Richter M, Zeichen J, Hufner T and Krettek C: Achilles tendon and paratendon microcirculation in midportion and insertional tendinopathy in athletes. Am J Sports Med 34: 92-97, 2006.
4. Mosier SM, Pomeroy G and Manoli A II: Pathoanatomy and etiology of posterior tibial tendon dysfunction. Clin Orthop Relat Res: 12-22, 1999.
5. Chong AK, Ang AD, Goh JC, Hui JH, Lim AL, Lee EH and Lim BH: Bone marrow-derived mesenchymal stem cells influence early tendon-healing in a rabbit achilles tendon model. J Bone Joint Surg Am 89: 74-81, 2007.
6. Zantop T, Gilbert TW, Yoder MC and Badyak SF: Extracellular matrix scaffolds are repopulated by bone marrow-derived cells in a mouse model of achilles tendon reconstruction. J Orthop Res 24: 1299-1309, 2006.
18. Yao L, Bestwick CS, Bestwick LA, Maffulli N and Aspden RM: Phenotypic drift in human tenocyte culture. Tissue Eng 12: 1843-1849, 2006.

19. Wang XJ, Dong Z, Zhong XH, Shi RZ, Huang SH, Lou Y and Li QP: Transforming growth factor-beta1 enhanced vascular endothelial growth factor synthesis in mesenchymal stem cells. Biochem Biophys Res Commun 365: 548-554, 2008.

20. Luo Q, Song G, Song Y, Xu B, Qin J and Shi Y: Indirect co-culture with tenocytes promotes proliferation and mRNA expression of tendon/ligament related genes in rat bone marrow mesenchymal stem cells. Cytotherapy 6: 1-10, 2009.

21. Uysal AC and Mizuno H: Tendon regeneration and repair with adipose derived stem cells. Curr Stem Cell Res Ther 5: 161-167, 2010.

22. Gargett CE and Masuda H: Adult stem cells in the endometrium. Mol Hum Reprod 16: 818-834, 2010.

23. Meng X, Ichim TE, Zhong J, Rogers A, Yin Z, Jackson J, Wang H, Ge W, Bogin V, Chan KW, et al: Endometrial regenerative cells: A novel stem cell population. J Transl Med 5: 57, 2007.

24. Patel AN, Park E, Kuzman M, Benetti F, Silva FJ and Allickson JG: Multipotent menstrual blood stromal stem cells: Isolation, characterization, and differentiation. Cell Transplant 17: 303-311, 2008.

25. Cui CH, Uyama T, Miyado K, Terai M, Kyo S, Kiyono T and Umezawa A: Menstrual blood-derived cells confer human dystrophin expression in the murine model of Duchenne muscular dystrophy via cell fusion and myogenic transdifferentiation. Mol Biol Cell 18: 1586-1594, 2007.

26. Jelinsky SA, Archambault J, Li L and Seekerman H: Tendon-selective genes identified from rat and human musculoskeletal tissues. J Orthop Res 28: 289-297, 2010.

27. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

28. Cui CH, Uyama T, Miyado K, Terai M, Kyo S, Kiyono T and Umezawa A: Menstrual blood-derived cells confer human dystrophin expression in the murine model of Duchenne muscular dystrophy via cell fusion and myogenic transdifferentiation. Mol Biol Cell 18: 1586-1594, 2007.

29. Cho NH, Park YK, Kim YT, Yang H and Kim SK: Lifetime expression of stem cell markers in the uterine endometrium. Fertil Steril 81: 403-407, 2004.

30. Young M: Stem cell applications in tendon disorders: A clinical perspective. Stem Cells Int 2012: 637836, 2010.

31. Qiu Y, Wang X, Zhang Y, Rrot R, Carr AJ, Zhu L, Xia Z and Sabokbar A: Development of a refined tenocyte differentiation culture technique for tendon tissue engineering. Cells Tissues Organs 197: 27-36, 2013.

32. Grisendi G, Annerén C, Cafarelli L, Sternieri R, Veronesi E, Cervo GL, Luminari S, Maur M, Frassoldati A, Palazzi G, et al: GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. Cytotherapy 12: 466-477, 2010.